The efficacy of a new, biocompatible, specific immunosorbent for hemoperfusive removal of digoxin is described. The sorbent contains antidigoxin antibodies covalently bound to polyacrolein microspheres, 0.2 μ diam. Thousands of microspheres are matrix-encapsulated in crosslinked agarose to form beads of 500 to 800 μ diam. Digoxin intoxicated dogs showed heart block, ventricular and atrial tachycardia and extended runs of PVCs. During hemoperfusion the abnormal ECG abated; at 2 h of hemoperfusion the ECG tracings returned to normal. Up to 25% of the total digoxin burden was removed. The numbers of the blood cells and the content of a battery of relevant soluble components of the blood remained constant. Dogs were alive and well after the hemoperfusion. Non hemoperfused dogs, which received antiarrythmic agents, did not survive the intoxication. This is the first report of a practical hemoperfusive system for the specific removal of digoxin from whole blood.
|Number of pages||12|
|Journal||Artificial Cells, Nanomedicine and Biotechnology|
|Issue number||2 --Jan|
|State||Published - Jan 1984|
Bibliographical noteFunding Information:
We tlinnk Gitan Eshcl, Migada Co, Kiryat Weizmann, Rehovot, Israel, for co111iscl during thc designisg aid fabrication of scvcral prototypes of c;innulil3 2nd )Icrnripcrfuriori outllov arid inllow 3cts mid for providing our l:i[xwat,ory witli IJI 'iry FCLi lor (~valuDiie ri iirltil the currciit models anti Dr. S11aiii ii Gilcr, dircc1,or arid Mi( 1i;icl DaliI, both of tlic lrwt oi Pliysioi and 15 ~ t';liirj "rv IT l J 4 n ,on i'vvl(~Ikn1c h t r. I'cl ah 'l'ilwtli, for gcmcrously prc-vdiiiL space fur thc caw, suigcricj and hclrlopcrluuiuns. 'l'hc rcbcarcd WLS supportcd in part by Galil Advanced Technologies, Ltd., Ramat-Gan, Israel.
- Antidigoxin antibodies
- Beads specific for removal of digoxin
- Polyacrolein microspheres
- Therapy of digoxin intoxication